Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
A virtual ESC sees Vascepa’s plaque reduction, Ionis’s second-gen candidates and Medtronic’s cryoblation win.
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.